Spongistatins as Tubulin Targeting Agents

Author(s): F. M. Uckun, C. Mao, S. -T. jan, H. Huang, A. O. Vassilev, C. S. Navara, R. K. Narla

Journal Name: Current Pharmaceutical Design

Volume 7 , Issue 13 , 2001

Become EABM
Become Reviewer
Call for Editor


Recently identified novel agents that disrupt tubulin polymerization include synthetic spiroketal pyrans (SPIKET) targeting the spongistatin binding site of beta tubulin. These agents exhibit anticancer activity by disrupting normal mitotic spindle assembly and cell division as well as inducing apoptosis. At nanomolar concentrations, the SPIKET compound SPIKET-P caused tubulin depolymerization in cell-free turbidity assays and exhibited potent cytotoxic activity against cancer cells as evidenced by destruction of microtubule organization, and prevention of mitotic spindle formation in human breast cancer cells. SPIKET compounds represent a new class of tubulin targeting agents that show promise as anti-cancer drugs.

Keywords: Spongistatins, Tubulin Targeting Agents, spiroketal pyrans (SPIKET), anticancer activity, SPIKET, SPIKET-P, anti-cancer drugs, Spiroketal Pyrans (SPIKET-P), Beta Tubulin, colchicine

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2001
Published on: 01 March, 2012
Page: [1291 - 1296]
Pages: 6
DOI: 10.2174/1381612013397492
Price: $65

Article Metrics

PDF: 2